For the quarter ended June 2023, Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) reported revenue of $3.88 billion, up 2.4% over the same period last year. EPS came in at $0.56, compared to $0.68 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $3.69 billion, representing a surprise of +4.98%. The company delivered an EPS surprise of +3.70%, with the consensus EPS estimate being $0.54.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Teva Pharmaceutical Industries Ltd. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenue- International Markets: $479 million compared to the $451.17 million average estimate based on three analysts. The reported number represents a change of +5.5% year over year.
- Geographic Revenue- North America: $1.99 billion versus the three-analyst average estimate of $1.81 billion. The reported number represents a year-over-year change of +4.6%.
- Geographic Revenue- North America- COPAXONE: $64 million compared to the $73.72 million average estimate based on three analysts. The reported number represents a change of -31.9% year over year.
- Geographic Revenue- North America- BENDEKA / TREANDA: $69 million versus the three-analyst average estimate of $58.17 million. The reported number represents a year-over-year change of -16.9%.
- Geographic Revenue- North America- AUSTEDO: $308 million versus $252.61 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +51% change.
- Geographic Revenue- North America- Anda: $392 million versus the three-analyst average estimate of $328.39 million. The reported number represents a year-over-year change of +27.3%.
- Geographic Revenue- Europe- COPAXONE: $60 million versus the three-analyst average estimate of $50.79 million. The reported number represents a year-over-year change of -16.7%.
- Geographic Revenue- Europe- Respiratory products: $66 million versus $63.46 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +1.5% change.
- Geographic Revenue- International Markets- Generic products: $394 million compared to the $385.70 million average estimate based on three analysts.
- Geographic Revenue- International Markets- COPAXONE: $10 million compared to the $8.39 million average estimate based on three analysts. The reported number represents a change of +11.1% year over year.
- Geographic Revenue- North America- AJOVY: $57 million versus $55 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +16.3% change.
- Revenue- API sales to third parties: $152 million versus $158.82 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -14.1% change.
View all Key Company Metrics for Teva Pharmaceutical Industries Ltd. here>>>Shares of Teva Pharmaceutical Industries Ltd. have returned +10.8% over the past month versus the Zacks S&P 500 composite's +3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
For the quarter ended June 2023, Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) reported revenue of $3.88 billion, up 2.4% over the same period last year. EPS came in at $0.56, compared to $0.68 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $3.69 billion, representing a surprise of +4.98%. The company delivered an EPS surprise of +3.70%, with the consensus EPS estimate being $0.54.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Teva Pharmaceutical Industries Ltd. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenue- International Markets: $479 million compared to the $451.17 million average estimate based on three analysts. The reported number represents a change of +5.5% year over year.
- Geographic Revenue- North America: $1.99 billion versus the three-analyst average estimate of $1.81 billion. The reported number represents a year-over-year change of +4.6%.
- Geographic Revenue- North America- COPAXONE: $64 million compared to the $73.72 million average estimate based on three analysts. The reported number represents a change of -31.9% year over year.
- Geographic Revenue- North America- BENDEKA / TREANDA: $69 million versus the three-analyst average estimate of $58.17 million. The reported number represents a year-over-year change of -16.9%.
- Geographic Revenue- North America- AUSTEDO: $308 million versus $252.61 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +51% change.
- Geographic Revenue- North America- Anda: $392 million versus the three-analyst average estimate of $328.39 million. The reported number represents a year-over-year change of +27.3%.
- Geographic Revenue- Europe- COPAXONE: $60 million versus the three-analyst average estimate of $50.79 million. The reported number represents a year-over-year change of -16.7%.
- Geographic Revenue- Europe- Respiratory products: $66 million versus $63.46 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +1.5% change.
- Geographic Revenue- International Markets- Generic products: $394 million compared to the $385.70 million average estimate based on three analysts.
- Geographic Revenue- International Markets- COPAXONE: $10 million compared to the $8.39 million average estimate based on three analysts. The reported number represents a change of +11.1% year over year.
- Geographic Revenue- North America- AJOVY: $57 million versus $55 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +16.3% change.
- Revenue- API sales to third parties: $152 million versus $158.82 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -14.1% change.
View all Key Company Metrics for Teva Pharmaceutical Industries Ltd. here>>>Shares of Teva Pharmaceutical Industries Ltd. have returned +10.8% over the past month versus the Zacks S&P 500 composite's +3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Get the latest research report on TEVA - FREE